Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Re: "effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy".

Skowronski DM, De Serres G, Janjua NZ, Hottes TS.

Am J Epidemiol. 2013 Mar 15;177(6):593-4. doi: 10.1093/aje/kwt021. Epub 2013 Feb 22. No abstract available.

2.

Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy.

Mannino S, Villa M, Apolone G, Weiss NS, Groth N, Aquino I, Boldori L, Caramaschi F, Gattinoni A, Malchiodi G, Rothman KJ.

Am J Epidemiol. 2012 Sep 15;176(6):527-33. Epub 2012 Aug 31.

3.
4.
5.

Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects.

Gasparini R, Schioppa F, Lattanzi M, Barone M, Casula D, Pellegrini M, Veitch K, Gaitatzis N.

Int J Clin Pract. 2010 Mar;64(4):432-8. doi: 10.1111/j.1742-1241.2009.02309.x. Epub 2009 Dec 17.

PMID:
20039974
6.

Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months.

Esposito S, Pugni L, Daleno C, Ronchi A, Valzano A, Serra D, Mosca F, Principi N.

Pediatrics. 2011 May;127(5):e1161-8. doi: 10.1542/peds.2010-1920. Epub 2011 Apr 4.

PMID:
21464195
7.

Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age.

Puig-Barberà J, Diez-Domingo J, Pérez Hoyos S, Belenguer Varea A, González Vidal D.

Vaccine. 2004 Dec 2;23(3):283-9.

PMID:
15530669
8.

Selection bias in the comparison between adjuvanted and unadjuvanted influenza vaccine effectiveness.

De Serres G.

Vaccine. 2014 Nov 20;32(49):6596. doi: 10.1016/j.vaccine.2013.12.032. Epub 2013 Dec 28. No abstract available.

PMID:
24380683
9.

A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.

Hatz C, von Sonnenburg F, Casula D, Lattanzi M, Leroux-Roels G.

Vaccine. 2012 May 14;30(23):3470-7. doi: 10.1016/j.vaccine.2012.03.017. Epub 2012 Mar 22.

PMID:
22446638
10.

Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis.

Black S, Della Cioppa G, Malfroot A, Nacci P, Nicolay U, Pellegrini M, Sokal E, Vertruyen A.

Vaccine. 2010 Oct 21;28(45):7331-6. doi: 10.1016/j.vaccine.2010.08.075. Epub 2010 Sep 15.

PMID:
20813217
11.

Influenza vaccine in young children.

Heikkinen T, Heinonen S.

N Engl J Med. 2012 Jan 26;366(4):383; author reply 383-4. doi: 10.1056/NEJMc1113381#SA2. No abstract available.

PMID:
22276840
12.

Influenza vaccine in young children.

Ambrose CS, Belshe RB.

N Engl J Med. 2012 Jan 26;366(4):383; author reply 383-4. doi: 10.1056/NEJMc1113381#SA1. No abstract available.

PMID:
22276839
13.

More on influenza vaccine in young children.

Sancho A, Melchiorri D, Abadie E; Committee for Medicinal Products for Human Use, European Medicines Agency.

N Engl J Med. 2012 Jun 28;366(26):2528; author reply 2528-9. doi: 10.1056/NEJMc1205643#SA1. No abstract available.

PMID:
22738111
14.

Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.

Langley JM, Reich D, Aggarwal N, Connor D, Lebel MH, Gupta A, Garfield H, Li P, Madan A, Vaughn DW.

Pediatr Infect Dis J. 2012 Aug;31(8):848-58. doi: 10.1097/INF.0b013e31825e6cd6.

PMID:
22801094
15.

MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk.

Durando P, Icardi G, Ansaldi F.

Expert Opin Biol Ther. 2010 Apr;10(4):639-51. doi: 10.1517/14712591003724662. Review.

PMID:
20218923
16.

MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.

Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G.

Vaccine. 2009 Nov 16;27(49):6959-65. doi: 10.1016/j.vaccine.2009.08.101. Epub 2009 Sep 12.

PMID:
19751689
17.

Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.

Pariani E, Boschini A, Amendola A, Poletti R, Anselmi G, Begnini M, Ranghiero A, Cecconi G, Zanetti AR.

Vaccine. 2011 Nov 15;29(49):9209-13. doi: 10.1016/j.vaccine.2011.09.103. Epub 2011 Oct 3.

PMID:
21974995
18.

Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.

Fukase H, Furuie H, Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, Yotsuyanagi H, Kusadokoro H, Sawata H, Nakura N, Lattanzi M.

Vaccine. 2012 Jul 13;30(33):5030-7. doi: 10.1016/j.vaccine.2012.03.053. Epub 2012 Apr 1.

PMID:
22472791
19.

[Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly].

Li RC, Fang HH, Li YP, Liu YP, Nong Y, Huang GB.

Zhonghua Liu Xing Bing Xue Za Zhi. 2008 Jun;29(6):548-51. Chinese.

PMID:
19040034
20.

Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals.

Kajaste-Rudnitski A, Galli L, Nozza S, Tambussi G, Di Pietro A, Pellicciotta G, Monti A, Mascagni P, Moro M, Vicenzi E.

AIDS. 2011 Jan 14;25(2):177-83. doi: 10.1097/QAD.0b013e328341afa8.

PMID:
21150561
Items per page

Supplemental Content

Write to the Help Desk